What happened in the Raymond James initiation for CLYM?

On March 10, 2026 Raymond James started Climb Bio, Inc. coverage with a Strong Buy. The initiation did not publish a public price target, and StreetInsider recorded the note.

Does the Raymond James note include a CLYM price target?

No. The StreetInsider summary of the Raymond James initiation shows no published price target and lists price at time as N/A. The call is directional without a quantified target.

How should investors use this CLYM analyst rating?

Treat the Raymond James Strong Buy as a positive signal but not a sole investment trigger. Combine the initiation with clinical timelines, cash runway, and market data before adjusting positions.

What is Meyka AI’s current view on CLYM?

Meyka AI rates CLYM with a grade of B, based on benchmark comparison, sector performance, growth metrics, and analyst coverage. This grade is informational and not investment advice.

Analyst Ratings

Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026

ByHuzaifa Zahoor March 12, 2026March 12, 2026

Raymond James initiated Climb Bio, Inc. (CLYM) with a Strong Buy on March 10, 2026. This CLYM analyst rating is an initial coverage call from a major firm and signals conviction in the company’s near-term pipeline and market positioning. The StreetInsider note did not list a price at time of coverage. Investors should read the initiation alongside recent trading data and our Meyka AI signals.